Nov 16 (Reuters) – CG Oncology said on Monday its experimental immunotherapy reduced the risk of tumor recurrence by 68% in certain patients with a type of bladder cancer, meeting the main goal of a late-stage study.
Its shares jumped more than 30% to $98 in premarket trading.
• The 367-patient trial was testing cretostimogene grenadenorepvec in patients with intermediate-risk non-muscle-invasive bladder cancer (NMIBC) following complete tumor resection
• Cretostimogene was generally well tolerated, with safety results consistent with those reported in previous studies, the company said
• About 75% of newly diagnosed bladder cancers are NMIBC. Many people with NMIBC can be treated successfully, but the cancer can come back, and some tumors can grow into the bladder muscle
• Cretostimogene is also being studied for BCG-unresponsive NMIBC, where the disease persists or recurs despite adequate treatment with Bacillus Calmette-Guerin
• The company now expects to submit its application to the US Food and Drug Administration before the end of March 2027 in order to incorporate additional data and a broader patient population
• CG Oncology will present more data at a conference in December
(Reporting by Sriparna Roy in Bengaluru; Editing by Shilpi Majumdar)

